Resources for MuGard® Oral Mucoadhesive

For additional information about MuGard, please click on the links below to download materials or contact the Soleva Assist Patient Reimbursement and Support Center toll-free at 1-877-319-7272

Allison RR, Ambrad AA, Arshoun Y, et al. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. 2014;120(9):1433-1440. 

Download Article

Prescription Order Form

Download Order Form

Full Prescribing Information

Download Full PI

Healthcare Professional Information

MuGard Brochure

Download Healthcare Professional Information

Easing the Effects of Radiation Therapy to the Head and Neck

Carrie Daly Easing the Effects of Radiation Therapy to the Head and Neck

Download PDF

Support services are available through Soleva Assist, including:

  • Medical information
  • How to obtain product
  • Report an adverse event or product complaint
  • Reimbursement support
  • Patient assistance

For more information, contact Soleva Assist toll-free at 1-877-319-7272

Indication and Important Safety Information

Indication: MuGard® Oral Mucoadhesive is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Contraindications: MuGard is contraindicated in patients with known hypersensitivity to any of the ingredients in the formulation.

Special Precautions for Use: Patients should avoid eating or drinking for at least one hour after using MuGard. After use, patients should replace the bottle cap and tightly seal the bottle. This product should not be used after the expiration date shown on the carton and product label. Do not use this product in patients with known sensitivity to any of the product’s ingredients. Dilution of the product prior to use is not recommended.

You may report a MuGard® adverse event to Soleva Pharma at 877-319-7272 or by emailing to

Please see accompanying full Prescribing Information.